ArticleCureus2024
Transient Psychotic Relapse Following COVID-19 in a Stable Schizophrenia Patient on Paliperidone Palmitate: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic psychiatric disorder marked by severe disturbances in thought, perception, and behavior. Long-acting injectable (LAI) antipsychotics, such as paliperidone, are widely used to promote sustained remission and ensure medication adherence, especially in patients prone to relapse. However, the COVID-19 pandemic has introduced unique challenges, with studies indicating that infections like COVID-19 may exacerbate psychiatric symptoms through neuroinflammatory pathways. This report presents the case of Ms. X, a 48-year-old Emirati female patient with chronic schizophrenia, who achieved long-term stability on paliperidone LAI at 150 mg monthly. For almost two years, she remained stable with notable improvements in delusional and paranoid symptoms, supported by structured therapeutic care, supportive psychotherapy, occupational therapy, and family involvement. However, in August 2024, Ms. X contracted COVID-19, which triggered a sudden relapse marked by acute persecutory delusions, heightened suspicion, and avoidance behavior, despite ongoing adherence to her LAI regimen. Following her recovery from COVID-19, Ms. X's psychotic symptoms remitted without changes to her antipsychotic treatment, and she returned to her baseline functioning. This case highlights the sensitivity of chronic schizophrenia to physiological stressors such as viral infections, underscoring the importance of vigilant monitoring and comprehensive care during periods of illness. It also contributes to the growing body of evidence suggesting that infections can induce transient yet significant psychiatric relapses in otherwise stable schizophrenia patients, emphasizing the intricate interplay between physical and mental health. This case underscores the complex interplay between physical and mental health in schizophrenia and highlights the need for further research into infection-induced psychiatric exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.